Advice

Following a full submission.

Not recommended for use within NHS Scotland.

This pegylated liposomal formulation of doxorubicin hydrochloride is now licensed as monotherapy for the treatment of metastatic breast cancer where there is an increased cardiac risk. An inconclusive study has suggested that it was not inferior to conventional doxorubicin in terms of progression-free survival. It was less cardiotoxic than conventional doxorubicin, but was associated with other troublesome adverse events, particularly palmarplantar erythrodysesthesia. The product is significantly more expensive than the standard preparation and its cost-effectiveness in managing metastatic breast cancer has not been addressed by the company in their submission.

Download detailed advice20KB (PDF)

Download

Medicine details

Medicine name:
Pegylated liposomal doxorubicin (Caelyx®)
SMC ID:
84/03
Indication:
Metastatic breast cancer
Pharmaceutical company
Schering-Plough Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Not recommended
Date advice published:
12 January 2004